Fibrosis Assessment Articles & Analysis
3 news found
These data show that Inversago’s INV-101 (zevaquenabant), a small molecule, peripherally-acting CB1 blocker, reduces fibrosis in a bleomycin model of Idiopathic Pulmonary Fibrosis (IPF). As compared with the vehicle treated group, zevaquenabant shows a statistically significant reduction in the Ashcroft score, the primary endpoint in this study, measured by ...
More specifically, INV-202 reduced glomerular injury, renal fibrosis and injury to proximal tubular epithelial cells, and also preserved podocyte structure and function. ...
Approximately 500 Canadians ages 6-11 are now eligible for TRIKAFTA®- Vertex has submitted this indication to CADTH & INESSS for Health Technology Assessments- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has granted Marketing Authorization for the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) ...